Citing appeals court 'anarchy,' Amgen asks SCOTUS to weigh its PCSK9 patent spat with Sanofi

Amgen made an aggressive legal bid to push Sanofi and Regeneron's rival PCSK9 drug off the market when the two were first duking it out in 2015. It didn't work—but Amgen hasn't given up. It's aiming to take the battle to the U.S. Supreme Court instead.